Accession Number:



Intranasal Oxytocin for the Treatment of Pain Associated with Interstitial Cystitis

Descriptive Note:

Technical Report,01 Sep 2011,31 Aug 2015

Corporate Author:

University of Alabama at Birmingham Birmingham United States

Personal Author(s):

Report Date:


Pagination or Media Count:



The purpose of this study was to evaluate the efficacy of intranasal oxytocin on bladder nociception in a cohort of patients with interstitial cystitis IC. We hypothesized that patients with IC are more likely to experience treatment responses as defined by global response assessment GRA scores when they receive intranasal oxytocin as opposed to when they receive intranasal saline. Secondary outcome measures included a verbal pain report VPR 0-10 with 0 being no pain and10 being the worst possible pain, a verbal anxiety report VAR 0-10 with 0 being no anxiety and 10 being the worst possible anxiety, number of voids since last contact with an investigator, and interim medications used for pain control or anxiety. Compared to saline administration intranasal oxytocin did not significantly decrease anxiety, pain or the number of voids reported by participants.

Subject Categories:

Distribution Statement: